Free Trial
NASDAQ:ONCT

Oncternal Therapeutics (ONCT) Stock Price, News & Analysis

Oncternal Therapeutics logo
$0.53 0.00 (0.00%)
As of 04/29/2025

About Oncternal Therapeutics Stock (NASDAQ:ONCT)

Key Stats

Today's Range
$0.53
$0.53
50-Day Range
$0.53
$0.53
52-Week Range
$0.53
$9.88
Volume
N/A
Average Volume
65,137 shs
Market Capitalization
$1.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Hold

Company Overview

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

Oncternal Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

ONCT MarketRank™: 

Oncternal Therapeutics scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncternal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oncternal Therapeutics has received no research coverage in the past 90 days.

  • Read more about Oncternal Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oncternal Therapeutics are expected to grow in the coming year, from ($12.43) to ($10.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncternal Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncternal Therapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oncternal Therapeutics has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ONCT.
  • Dividend Yield

    Oncternal Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Oncternal Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ONCT.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oncternal Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncternal Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.20% of the stock of Oncternal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 16.05% of the stock of Oncternal Therapeutics is held by institutions.

  • Read more about Oncternal Therapeutics' insider trading history.
Receive ONCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONCT Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Oncternal Therapeutics Reports Q3 2024 Earnings
Oncternal Therapeutics to Cut Most of Its Workforce
See More Headlines

ONCT Stock Analysis - Frequently Asked Questions

Oncternal Therapeutics' stock was trading at $0.5266 at the beginning of the year. Since then, ONCT stock has increased by 0.0% and is now trading at $0.5266.
View the best growth stocks for 2025 here
.

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its earnings results on Thursday, August, 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.03) by $0.14. The business had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.24 million. Oncternal Therapeutics had a negative trailing twelve-month return on equity of 177.58% and a negative net margin of 1,599.95%.
Read the conference call transcript
.

Shares of Oncternal Therapeutics reverse split on Monday, January 8th 2024. The 1-20 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncternal Therapeutics investors own include NIO (NIO), Walt Disney (DIS), Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

Last Earnings
8/08/2024
Today
5/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONCT
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$18.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+1,799.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-39,480,000.00
Net Margins
-1,599.95%
Pretax Margin
-1,599.95%

Debt

Sales & Book Value

Annual Sales
$790,000.00
Price / Cash Flow
N/A
Book Value
$10.19 per share
Price / Book
0.05

Miscellaneous

Free Float
2,628,000
Market Cap
$1.56 million
Optionable
No Data
Beta
1.18
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ONCT) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners